Publications utilizing NanoSomiX proprietary technology

The following publications demonstrate the application of NanoSomiX proprietary technology across multiple neurological conditions. Each study represents peer-reviewed research that has utilized our innovative approach to extracellular vesicle analysis.

Acute Brain Injury:

  • Mathew A. Edwardson, Masato Mitsuhashi, and Dennis Van Epps. Elevation of astrocyte-derived extracellular vesicles over the first month post-stroke in humans. Scientific Reports, nature portfolio (2024) 14:5272. https://doi.org/10.1038/s41598-024-55983-w
  • Hotta N, Tadokoro T, Henry J, et al. Monitoring of Post-Brain Injuries By Measuring Plasma Levels of Neuron-Derived Extracellular Vesicles. Biomarker Insights. 2022;17. https://doi.org/10.1177/11772719221128145
  • Kawata, K., Mitsuhashi, M., Aldret, R. A preliminary report on brain-derived extracellular vesicle as novel blood biomarkers for sport-related concussions, Front. Neurol., 12 April 2018. https://doi.org/10.3389/fneur.2018.00239


Alzheimer's disease (AD):

  • Kapogiannis D, Mustapic M, Shardell MD, et al. Association of Extracellular Vesicle Biomarkers with Alzheimer Disease in the Baltimore Longitudinal Study of Aging. JAMA Neurol. 2019 Jul 15. DOI: 10.1001/jamaneurol.2019.2462
  • Goetzl EJ, Kapogiannis D, Schwartz JB, et al. Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer's disease. The FASEB Journal, Dec. 2016 , doi: 10.1096/fj.201600816R
  • Abner EL, Jicha GA, et al. Plasma neuronal exosomal levels of Alzheimer's disease biomarkers in normal aging. Annals of Clinical and Translational Neurology, 2016, https://doi.org/10.1002/acn3.309
  • Winston CN, Goetzl, EJ, et al. Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile. Alzheimer's & Dementia (Diagnosis, Assessment & Disease Monitoring) 2016 http://dx.doi.org/10.1016/j.dadm.2016.04.001
  • Goetzl EJ, Boxer a, Schwartz JB, et al. Altered lysosomal proteins in neural derived plasma exosomes in preclinical Alzheimer disease. Neurology 2015; doi:10.1212/WNL.0000000000001702
  • Goetzl EJ, Boxer A, Schwartz JB, et al. Low neural exosome levels of cellular survival factors in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2015, doi: 10.1002/acn3.211
  • Kapogiannis, et. al. The FASEB Journal, 2014: Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer's disease, https://doi.org/10.1096/fj.14-262048
  • Fiandaca, et.al. Alzheimer's & Dementia, 2014: Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study, DOI: https://doi.org/10.1016/j.jalz.2014.06.008


Amyotrophic Lateral Sclerosis (ALS):

  • Katsu M, Hama Y, Utsumi J et al. MicroRNA expression profiles of neuron-derived extracellular vesicles in plasma from patients with amyotrophic lateral sclerosis. Neuroscience Letters, August 2019, vol 708 https://doi.org/10.1016/j.neulet.2019.03.048


Major Depressive Disorder (MDD):

  • Kuwano N, Kato TA, Mitsuhashi M, Sato-Kasai M, Shimokawa N, Hayakawa K, Ohgidani M, Sagata N, Kubo H, Sakurai T, Kanba S. Neuron-related blood inflammatory markers as an objective evaluation tool for major depressive disorder: An exploratory pilot case-control study. J Affect Disord. 2018 Jul 17;240:88-98. https://doi.org/10.1016/j.jad.2018.07.040


Parkinson's disease and Related Disorders:

  • Ohmichi, T., Mitsuhashi, M. et al., Quantification of brain-derived extracellular vesicles in plasma as a biomarker to diagnose Parkinson's and related diseases, Parkinsonism & Related Disorders, April 2019; 61: 82-87 https://doi.org/10.1016/j.parkreldis.2018.11.021

To learn more about the advancements and applications of NanoSomiX technology, explore our dedicated news section.